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A
fter years of debate, Le Douarin’s elegant work
(1) established that pancreatic islet cells differ-
entiate from progenitors emerging from the
deﬁnitive gut endoderm rather than from neu-
roectoderm as had been inferred from co-expression of
neuronal markers. Although islet cells and the brain do not
share a common developmental origin, a fascinating pic-
ture has emerged in which they nonetheless share many
biochemical pathways and, hence, are characterized by
extensive overlap in gene expression. Brain and islet are
also tightly linked functionally through neural-entero-islet,
brain-islet, and islet-brain axes (2,3). Thus, the secretion of
insulin and other islet hormones are clearly regulated
by the hypothalamus and other brain areas, while con-
versely insulin action in the hypothalamus inﬂuences both
energy balance (4) and glucose metabolism (5). Not sur-
prisingly, therefore, targeted deletion or induction of
genes in either tissue can yield mice with overlapping
phenotypes where hormone secretion and glucose metab-
olism are concerned. The report by Wicksteed et al. (6) in
this issue of Diabetes sheds welcome light on the extent to
which commonly used mouse models for -cell–speciﬁc
gene targeting affect gene expression in the brain as well
as in the islet.
A commonly employed strategy for gene targeting in
vivo employs the Cre/LoxP system of DNA recombination
that allows for either deletion or de novo induction of
select gene-coding sequences in speciﬁc cell types in mice
(7–9). Tissue speciﬁcity with this method is achieved
through the use of cell type-speciﬁc promoters to drive
expression of Cre recombinase, an enzyme that cleaves
DNA sequences between ﬂanking LoxP sites. These pro-
moters can be further modiﬁed to incorporate drug-re-
sponsive elements, allowing Cre recombinase expression
to be switched on at will by drugs such as tamoxifen
(CreERT). The Cre/LoxP system has thus emerged as an
essential strategy with which to investigate the spatial and
temporal function of a given gene (10–13) and has also
helped deﬁne cell lineage relationships through the induc-
tion of reporter genes (14–16).
The capacity to alter islet cell function by directing Cre
expression to speciﬁc cell populations has been widely
and productively employed by diabetes investigators (for a
complete list of transgenic mice directing expression of
Cre in pancreatic cell populations, refer to http://www.
ﬁndmice.org/index.jsp and http://www.informatics.jax.
org/). Commonly employed mouse models use either the
rat insulin2 promoter (RIP) or the Pdx1 promoter to drive
Cre recombinase in -cells. Of three commonly used
RIP-Cre mouse lines, Cre is expressed constitutively in
two, while expression is tamoxifen-inducible in the third
(17–19). Similarly, Cre expression is constitutive in three
of four published Pdx1-Cre mouse lines, while it is tamox-
ifen-inducible in the fourth (20–23).
Because of differences in the timing of Cre-recombinase
expression, Pdx1-Cre mouse lines have been labeled
“early” or “late” recombinants (e.g., Pdx1-Cre
Early [21])
and Pdx1-Cre
Late [19]). The difference in timing of recom-
bination is important since in addition to other key
variables (e.g., tissue distribution and degree of recombi-
nation), the age at which altered gene expression occurs
can have a dramatic impact on phenotypic outcomes. This
effect is illustrated in a study (24) in which the use of
Cre-LoxP technology to introduce a stable mutant of
-catenin within the mouse pancreatic epithelium had
opposite effects depending on the spatial and temporal
pattern of gene induction (25). Thus, when this form of
-catenin was expressed during early organogenesis using
Pdx1-Cre
Early mice (21), a severe reduction of pancreas
mass associated with postnatal lethality was observed
(due to the loss of Pdx1 expression in early pancreatic
progenitors). By comparison, induction at a later time
point using Pdx1-Cre
Late mice (19) increased cellular
proliferation and induced a dramatic increase of pancreas
organ size (24). Should Cre recombinase be expressed in
other tissues, therefore, the phenotypic consequence may
also depend on the age at which recombination occurs.
In this issue of Diabetes, Wicksteed et al. (6) compared
Cre activity in the brain of commonly used mouse models
with that observed using a new mouse line generated using
a tamoxifen-inducible mouse insulin1 promoter to drive
Cre expression (MIP-Cre/ERT). The investigators report
that each of the three commonly used RIP-Cre transgenic
lines exhibit Cre-mediated recombination in the brain (Fig.
1). In one of these mouse lines (RIP-Cre
Mgn) (18) (Fig. 1B),
5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-gal)
staining was detected throughout the brain with the high-
est intensity in the midbrain and ventral regions, whereas
RIP-Cre
Herr mice displayed a weaker and more punctate
central nervous system expression pattern without obvi-
ous regionalization (19) (Fig. 1C). The tamoxifen-inducible
RIP-Cre/ERT mouse (17) also displayed strong, punctate
X-gal staining in the brain but with a more restricted
expression pattern (Fig. 1D). Analysis of Pdx1-Cre lines
also revealed X-gal staining in the brain, including one
(Pdx1-Cre
Early) (21) (Fig. 1E) in which Cre activity was
detected in distinct hypothalamic neuronal subsets impor-
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ing neurons and neurons shown to be activated by leptin.
Since expression of genes targeted using these mouse lines
will be altered in the brain as well as in the pancreas, these
ﬁndings offer a cautionary note to the interpretation of
resultant phenotypes.
Compared with the above Cre models, the new MIP-Cre/
ERT mice described by Wicksteed et al. display a more
-cell–speciﬁc recombination pattern with virtually unde-
tectable Cre activity in any brain regions analyzed (Fig.
1H). As this mouse model also features a tamoxifen-
inducible Cre, it offers the potential for both temporal and
tissue-speciﬁc control of gene deletion (or induction) in
pancreatic -cells and, hence, is a welcome addition to the
repertoire of animal models used by the diabetes research
community. Whether efﬁcient Cre-mediated recombina-
tion in MIP-Cre/ERT mice can be achieved in utero and
therefore can be used to target select genes during -cell
development is a question that awaits further study.
Although somewhat tangential to the question at hand, it
seems perplexing that the rat insulin2 promoter, but not
the mouse insulin1 promoter, is active in the mouse brain.
Several factors likely contribute to this discrepancy, in-
cluding the additional regulatory elements within the
larger promoter fragment employed in MIP-Cre/ERT mice,
but an important conclusion supported by this ﬁnding is
that the insulin gene does not appear to be expressed in
adult mammalian brain. This ﬁnding adds to a literature
that strongly supports this conclusion despite papers that
appear from time to time implying the opposite (most
recently in the Alzheimer disease literature) (26).
It seems likely that the question of whether altered
neuronal gene expression inﬂuenced the phenotype of
various published RIP-Cre or Pdx1-Cre mouse models will
soon be answered. In the meantime, however, RIP-Cre and
Pdx1-Cre models will continue to be important tools for
the study of islet development and function as long as a
neural contribution to a particular phenotype can be
reliably excluded, and improvements in this technology
will undoubtedly continue. As this progress unfolds, we
are reminded that the close functional link between brain
and islet can be a source of confusion and frustration, as
well as one of fascination.
ACKNOWLEDGMENTS
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. Le Douarin NM. On the origin of pancreatic endocrine cells. Cell 1988;53:
169–171
CTX
HIP
THA
LHA FX
DMN VMN ARC ME
A
BD
EG
RIP-CreMgn RIP-CreHerr RIP-Cre/ERT
PDX1-CreDam PDX1-CreTuv PDX1AI-III-Cre/ERT MIP-Cre/ERT
F H
C
FIG. 1. Schematic representation of Cre expression in a coronal section taken through the mid-hypothalamus of mice with pancreas-targeted Cre
drivers that were crossed with the R26R -galactosidase Cre reporter line. Shaded areas depict regions of Cre-mediated recombination based
subjectively on ﬁndings reported by Wicksteed et al. (6). A: R26R
wt/lacZ without a Cre driver. B: RIP-Cre
Mgn; R26R
wt/lacZ. C: RIP-Cre
Herr;
R26R
wt/lacZ. D: RIP-Cre/ERT; R26R
wt/lacZ. E: PDX1-Cre
Dam; R26R
wt/lacZ. F: PDX1-CreTuv; R26R
wt/lacZ. G: PDX1
AI-III-Cre/ERT; R26R
wt/lacZ. H:
MIP-Cre/ERT; R26R
wt/lacZ. Until more is known regarding the reproducibility of these expression patterns, this depiction is intended only as a
general guide. Investigators using these mice are advised to evaluate central nervous system Cre-mediated recombination on a case-by-case basis.
ARC, arcuate nucleus; CTX, cortex; DMN, dorsomedial nucleus; FX, formix; HIP, hippocampus; LHA, lateral hypothalamic area; ME, median area
eminence; THA, thalamus; VMN, ventro-medial nucleus.
HYPOTHALAMUS AND -CELL CONNECTION
2992 DIABETES, VOL. 59, DECEMBER 2010 diabetes.diabetesjournals.org2. Rohner-Jeanrenaud F, Bobbioni E, Ionescu E, Sauter JF, Jeanrenaud B.
Central nervous system regulation of insulin secretion. Adv Metab Disord
1983;10:193–220
3. Atouf F, Czernichow P, Scharfmann R. Expression of neuronal traits in
pancreatic beta cells. Implication of neuron-restrictive silencing factor/
repressor element silencing transcription factor, a neuron-restrictive si-
lencer. J Biol Chem 1997;272:1929–1934
4. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr. Insulin in the
brain: a hormonal regulator of energy balance. Endocr Rev 1992;13:387–414
5. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling
is required for inhibition of glucose production. Nat Med 2002;8:1376–1382
6. Wicksteed B, Brissova M, Yan W, Opland DM, Plank JL, Reinert RB,
Dickson LM, Tamarina NA, Philipson LH, Shostak A, Bernal-Mizrachi E,
Elghazi L, Row MW, Labosky PA, Myers MM Jr, Gannon M, Powers AC,
Dempsey PJ. Conditional gene targeting in mouse pancreatic -cells:
analysis of ectopic Cre transgene expression in the brain. Diabetes
2010;59:3090–3098
7. Sauer B. Manipulation of transgenes by site-speciﬁc recombination: use of
Cre recombinase. Methods Enzymol 1993;225:890–900
8. Marth JD. Recent advances in gene mutagenesis by site-directed recombi-
nation. J Clin Invest 1996;97:1999–2002
9. Rajewsky K, Gu H, Ku ¨hn R, Betz UA, Mu ¨ller W, Roes J, Schwenk F.
Conditional gene targeting. J Clin Invest 1996;98:600–603
10. Metzger D, Clifford J, Chiba H, Chambon P. Conditional site-speciﬁc
recombination in mammalian cells using a ligand-dependent chimeric Cre
recombinase. Proc Natl Acad SciUSA1995;92:6991–6995
11. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P.
Ligand-activated site-speciﬁc recombination in mice. Proc Natl Acad Sci U
S A 1996;93:10887–10890
12. Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D,
Chambon P. Skin abnormalities generated by temporally controlled RXRal-
pha mutations in mouse epidermis. Nature 2000;407:633–636
13. Vasioukhin V, Degenstein L, Wise B, Fuchs E. The magical touch: genome
targeting in epidermal stem cells induced by tamoxifen application to
mouse skin. Proc Natl Acad SciUSA1999;96:8551–8556
14. Herrera PL. Deﬁning the cell lineages of the islets of Langerhans using
transgenic mice. Int J Dev Biol 2002;46:97–103
15. Seymour PA, Freude KK, Dubois CL, Shih HP, Patel NA, Sander M. A
dosage-dependent requirement for Sox9 in pancreatic endocrine cell
formation. Dev Biol 2008;323:19–30
16. Thorel F, Ne ´pote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL.
Conversion of adult pancreatic alpha-cells to beta-cells after extreme
beta-cell loss. Nature 2010;464:1149–1154
17. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are
formed by self-duplication rather than stem-cell differentiation. Nature
2004;429:41–46
18. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton
KD, Lindner J, Cherrington AD, Magnuson MA. Dual roles for glucokinase
in glucose homeostasis as determined by liver and pancreatic beta
cell-speciﬁc gene knock-outs using Cre recombinase. J Biol Chem 1999;
274:305–315
19. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from
two independent cell lineages. Development 2000;127:2317–2322
20. Ofﬁeld MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan
BL, Wright CV. PDX-1 is required for pancreatic outgrowth and differen-
tiation of the rostral duodenum. Development 1996;122:983–995
21. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic
lineage: NGN3 cells are islet progenitors and are distinct from duct
progenitors. Development 2002;129:2447–2457
22. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA,
Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta
LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM,
Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its
early detection in the mouse. Cancer Cell 2003;4:437–450
23. Zhang H, Fujitani Y, Wright CV, Gannon M. Efﬁcient recombination in
pancreatic islets by a tamoxifen-inducible Cre-recombinase. Genesis 2005;
42:210–217
24. Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M. Stabilization of
beta-catenin impacts pancreas growth. Development 2006;133:2023–2032
25. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM.
Intestinal polyposis in mice with a dominant stable mutation of the
beta-catenin gene. EMBO J 1999;18:5931–5942
26. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM.
Insulin and insulin-like growth factor expression and function deteriorate
with progression of Alzheimer’s disease: link to brain reductions in
acetylcholine. J Alzheimers Dis 2005;8:247–268
M.W. SCHWARTZ, S.J. GUYENET, AND V. CIRULLI
diabetes.diabetesjournals.org DIABETES, VOL. 59, DECEMBER 2010 2993